MindBio Therapeutics Corp. (CSE:MBIO)

Canada flag Canada · Delayed Price · Currency is CAD
1.300
-0.200 (-13.33%)
Nov 14, 2025, 4:00 PM EST
-13.33%
Market Cap2.56M
Revenue (ttm)n/a
Net Income (ttm)-2.51M
Shares Out2.04M
EPS (ttm)-4.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume914
Average Volume2,133
Open1.370
Previous Close1.500
Day's Range1.300 - 1.370
52-Week Range1.300 - 12.000
Beta-0.37
RSI41.97
Earnings DateOct 29, 2025

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for de... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

News

There is no news available yet.